GlassScriptPhysician profile
Khushboo Surti
NPI 1942815782
$3,735.55
in general payments reported to CMS, 2019-2025
22 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,505 · 2022: $1,068 · 2023: $407 · 2024: $321 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,163.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $681.20 | 2021-2025 | Caplyta |
| Abbvie INC. | $638.07 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $424.69 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $332.77 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $260.42 | 2021-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $239.05 | 2021-2024 | Austedo Xr, Uzedy |
| Sunovion Pharmaceuticals INC. | $229.15 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $124.25 | 2021-2025 | Rexulti |
| Acadia Pharmaceuticals INC | $113.60 | 2021-2024 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $113.44 | 2021-2022 | |
| Lundbeck LLC | $112.67 | 2021-2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $95.00 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $75.60 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $64.33 | 2025 | Cobenfy |
| Corium, LLC | $53.92 | 2024-2025 | Azstarys |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $37.78 | 2021 | |
| Supernus Pharmaceuticals, INC. | $33.51 | 2022-2025 | Qelbree |
| Orexo US, INC. | $26.27 | 2021 | |
| Sage Therapeutics, LLC | $23.97 | 2025 | Zurzuvae |
| Vanda Pharmaceuticals INC. | $22.25 | 2022 | |
| Axsome Therapeutics, INC. | $21.39 | 2023 | Auvelity |
| Almatica Pharma LLC | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khushboo Surti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.